5 of Last Week's Biggest Winners
What's better than momentum? Mo' momentum. Let's take a closer look at five of this past week's biggest scorchers.
Company | Dec. 6 | Weekly Gain |
|---|---|---|
Plug Power | $2.06 | 178% |
XOMA | $6.02 | 26% |
Gogo | $32.89 | 23% |
Cheniere Energy | $44.90 | 13% |
Marketo | $32.38 | 11% |
Source: Barron's.
Let's start with Plug Power. The fuel-cell maker was the market's biggest winner, nearly tripling on the week after announcing that it will be profitable next year. Plug Power has been having a strong fourth quarter, and it now sees between $30 million and $40 million in orders for the current quarter. When you factor in its forecast for shipments in 2014 and the recurring revenue from product, service, and hydrogen contracts, this historically profitless company is in good shape to be in the black next year.
XOMA moved higher after its CEO had an encouraging presentation at a Piper Jaffray health-care conference on Wednesday afternoon. He updated the attendees on the biotech's pipeline, providing some color on the potential of XOMA's promising treatments.
Gogo was another winner, after the in-flight Wi-Fi provider received certification to install its online connectivity platform in Boeing 747-400 aircraft. This is an important milestone, since getting its Ku-satellite technology in Boeing 747-400 planes is a way to take its growing domestic reach global.
Cheniere Energy signed its first deal to deliver liquefied natural gas from its Corpus Christi project. Pertamina will be buying roughly 0.8 million tonnes of liquefied natural gas a year. Cheniere also revealed plans to take a fully owned subsidiary public.
Finally, we have Marketo on the move. The cloud-based marketing software provider had its CEO speak at the 2013 Credit Suisse Technology Conference, helping expand the awareness of the recent IPO's business and prospects. It also kicked off the week by announcing a deal with biotech IT services provider HighPoint Solutions.
Keep the winners coming with these two game-changers
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.
The article 5 of Last Week's Biggest Winners originally appeared on Fool.com.
Longtime Fool contributor Rick Munarriz and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
